Efficacy and Safety of the Aflibercept Biosimilar SB15 in Neovascular Age-Related Macular Degeneration A Phase 3 Randomized Clinical Trial

Woo Se Joon, Bradvica Mario, Vajas Attila, Sagong Min, Ernest Jan, Studnicka Jan, Veith Miroslav, Wylegala Edward, Patel Sunil, Yun Cheolmin, Orski Michal, Astakhov Sergei, Tóth-Molnár Edit, Csutak Adrienne, et al
2023

Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema 1‑year results from the Japan subgroup of t...

Shimura Masahiko, Kitano Shigehiko, Ogata Nahoko, Mitamura Yoshinori, Oh Hideyasu, Kollaborációs szervezet: YOSEMITE and RHINE Investigators, Bátor György, Seres András, Szalczer Lajos, Tóth-Molnár Edit, Vajas Attila, Varsány Balázs, Kerény Ágnes, Papp András, Szecskó Tímea, Vogt Gábor
2023

Biosimilar SB15 versus reference aflibercept in neovascular age-related macular degeneration 1-year and switching results of a phase 3 clinical trial /

Woo Se Joon, Sadda SriniVas R, Bradvica Mario, Vajas Attila, Sagong Min, Ernest Jan, Studnička Jan, Veith Miroslav, Wylegala Edward, Patel Sunil, Yun Cheolmin, Orski Michal, Astakhov Sergei, Tóth-Molnár Edit, Csutak Adrienne, Enyedi Lajos, Choi Wooree, Oh Inkyung, Jang Hyerin
2023